Cancers, Vol. 12, Pages 808: Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients

Conclusions: The results of the present retrospective study demonstrate the suitability of the MSKCC model in mRCC patients treated with first-line sunitinib and suggest different outcomes between patients with one or two risk factors.

Source: Cancers - March 26, 2020 Category: Cancer & Oncology Authors: Ondrej Fiala Jindrich Finek Alexandr Poprach Bohuslav Melichar Jindrich Kopeck ý Milada Zemanova Katerina Kopeckova Tomas Mlcoch Tomas Dolezal Lenka Capkova Tomas Buchler Tags: Article Source Type: research